Therapeutic strategies targeting upstream obesity-related inflammation, through weight loss, anti-inflammatory agents, or insulin-sensitizing drugs, may offer dual benefits by attenuating both amyloid and tau progression, thus slowing or preventing AD trajectory. Here, MAPT is linked to obesity disorder.